

In October 2018 Amgen announced that it was making Repatha® (evolovumab) available at a reduced list price by introducing new National Drug Codes (NDCs). The new NDCs did not represent any change in form, strength or product composition of Repatha®. Since this time Amgen has made Repatha® available with the original and new NDCs. On December 31, 2019, Amgen discontinued sales of the product bearing the old NDC.

The table below reflects the old and new NDCs for Repatha®. Please note that each new NDC is a *replacement* for an old NDC, and thus each pair of old/new NDCs is treated as if it were the *same* NDC for purposes of pricing and purchasing from Amgen through the 340B program.

Old NDC	Description	New NDC
55513-0750-01	Repatha® 140 mg/mL single-use prefilled syringe	72511-0750-01
55513-0760-02	Repatha® 140 mg/mL single-use prefilled SureClick® autoinjector	72511-0760-02
55513-0770-01	Repatha® 420 mg/3.5 mL single-use Pushtronex® system	72511-0770-01

340B Inventory Replenishment:

Because the new NDCs are, in fact, the same product (drug, dose, formulation, or volume) with the same 340B price as the corresponding old NDCs, Amgen believes that a covered entity utilizing a 340B inventory replenishment model may count accumulations of the old NDCs toward replenishment of equal quantities of the corresponding new NDC (see above table).

Any questions regarding this matter can be directed to 340Brelations@amgen.com.